Return to homepagePandemic Pact

TURN-COVID: Dutch cohort study evaluating the use of neutralizing monoclonal SARS-CoV-2 antibodies

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.04301E+13

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2025

  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)

  • Principal Investigator

    dr WJ. prof Wiersinga MD PhD

  • Research Location

    N/A

  • Lead Research Institution

    Amsterdam UMC Locatie VUmc

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Despite vaccination, some patients with a compromised immune system have an increased risk of Covid-19 with a serious course. The use of neutralizing monoclonal SARS-CoV-2 antibodies is a breakthrough in the treatment of Covid-19 for this patient group. This new therapy prevents Covid-19 related hospitalizations and deaths, provided the drug is given early in the disease process. This could substantially reduce the pressure on hospitals. Goal TURN-COVID is a national cohort study focused on the use of neutralizing monoclonal SARS-CoV-2 antibodies as therapy against Covid-19 in high-risk patients. The aim of the study is to map the use, effectiveness, safety and costs of the different antibodies. In addition, a national platform is being created to evaluate future unregistered treatments for Covid-19.